128 related articles for article (PubMed ID: 15388473)
1. Antistaphylococcal activity of LBM415, a new peptide deformylase inhibitor, compared with those of other agents.
Credito K; Lin G; Ednie LM; Appelbaum PC
Antimicrob Agents Chemother; 2004 Oct; 48(10):4033-6. PubMed ID: 15388473
[TBL] [Abstract][Full Text] [Related]
2. Antipneumococcal activity of LBM415, a new peptide deformylase inhibitor, compared with those of other agents.
Ednie LM; Pankuch G; Appelbaum PC
Antimicrob Agents Chemother; 2004 Oct; 48(10):4027-32. PubMed ID: 15388472
[TBL] [Abstract][Full Text] [Related]
3. Antistaphylococcal activity of DX-619, a new des-F(6)-quinolone, compared to those of other agents.
Bogdanovich T; Esel D; Kelly LM; Bozdogan B; Credito K; Lin G; Smith K; Ednie LM; Hoellman DB; Appelbaum PC
Antimicrob Agents Chemother; 2005 Aug; 49(8):3325-33. PubMed ID: 16048943
[TBL] [Abstract][Full Text] [Related]
4. Activity of LBM415 compared to those of 11 other agents against Haemophilus species.
Bogdanovich T; Smith KA; Clark C; Pankuch GA; Lin G; McGhee P; Dewasse B; Appelbaum PC
Antimicrob Agents Chemother; 2006 Jul; 50(7):2323-9. PubMed ID: 16801408
[TBL] [Abstract][Full Text] [Related]
5. Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004).
Watters AA; Jones RN; Leeds JA; Denys G; Sader HS; Fritsche TR
J Antimicrob Chemother; 2006 May; 57(5):914-23. PubMed ID: 16549511
[TBL] [Abstract][Full Text] [Related]
6. Antistaphylococcal activity of CB-181963 (CAB-175), an experimental parenteral cephalosporin.
Hoellman DB; Pankuch GA; Appelbaum PC
Antimicrob Agents Chemother; 2004 Oct; 48(10):4037-9. PubMed ID: 15388474
[TBL] [Abstract][Full Text] [Related]
7. Antistaphylococcal activity of dalbavancin, an experimental glycopeptide.
Lin G; Credito K; Ednie LM; Appelbaum PC
Antimicrob Agents Chemother; 2005 Feb; 49(2):770-2. PubMed ID: 15673763
[TBL] [Abstract][Full Text] [Related]
8. Activities of antistaphylococcal antibiotics towards the extracellular and intraphagocytic forms of Staphylococcus aureus isolates from a patient with persistent bacteraemia and endocarditis.
Lemaire S; Kosowska-Shick K; Julian K; Tulkens PM; Van Bambeke F; Appelbaum PC
Clin Microbiol Infect; 2008 Aug; 14(8):766-77. PubMed ID: 18727801
[TBL] [Abstract][Full Text] [Related]
9. Role of the AcrAB-TolC efflux pump in determining susceptibility of Haemophilus influenzae to the novel peptide deformylase inhibitor LBM415.
Dean CR; Narayan S; Daigle DM; Dzink-Fox JL; Puyang X; Bracken KR; Dean KE; Weidmann B; Yuan Z; Jain R; Ryder NS
Antimicrob Agents Chemother; 2005 Aug; 49(8):3129-35. PubMed ID: 16048914
[TBL] [Abstract][Full Text] [Related]
10. Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center.
Bozdogan B; Esel D; Whitener C; Browne FA; Appelbaum PC
J Antimicrob Chemother; 2003 Nov; 52(5):864-8. PubMed ID: 14563898
[TBL] [Abstract][Full Text] [Related]
11. Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus.
Leuthner KD; Cheung CM; Rybak MJ
J Antimicrob Chemother; 2006 Aug; 58(2):338-43. PubMed ID: 16787952
[TBL] [Abstract][Full Text] [Related]
12. Activity of quinupristin/dalfopristin against extracellular and intracellular Staphylococcus aureus with various resistance phenotypes.
Baudoux P; Lemaire S; Denis O; Tulkens PM; Van Bambeke F; Glupczynski Y
J Antimicrob Chemother; 2010 Jun; 65(6):1228-36. PubMed ID: 20378672
[TBL] [Abstract][Full Text] [Related]
13. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05.
Steinkraus G; White R; Friedrich L
J Antimicrob Chemother; 2007 Oct; 60(4):788-94. PubMed ID: 17623693
[TBL] [Abstract][Full Text] [Related]
14. Susceptibility to daptomycin, quinupristin-dalfopristin and linezolid and some other antibiotics in clinical isolates of methicillin resistant and methicillin sensitive S.aureus from the Oslo area.
Jørgen B; Merckoll P; Melby KK
Scand J Infect Dis; 2007; 39(11-12):1059-62. PubMed ID: 17852934
[TBL] [Abstract][Full Text] [Related]
15. Comparative antimicrobial characterization of LBM415 (NVP PDF-713), a new peptide deformylase inhibitor of clinical importance.
Fritsche TR; Sader HS; Cleeland R; Jones RN
Antimicrob Agents Chemother; 2005 Apr; 49(4):1468-76. PubMed ID: 15793128
[TBL] [Abstract][Full Text] [Related]
16. Activity of ceftobiprole compared with those of other agents against Staphylococcus aureus strains with different resistotypes by time-kill analysis.
Lin G; Appelbaum PC
Diagn Microbiol Infect Dis; 2008 Feb; 60(2):233-5. PubMed ID: 17997257
[TBL] [Abstract][Full Text] [Related]
17. In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models.
Osborne CS; Neckermann G; Fischer E; Pecanka R; Yu D; Manni K; Goldovitz J; Amaral K; Dzink-Fox J; Ryder NS
Antimicrob Agents Chemother; 2009 Sep; 53(9):3777-81. PubMed ID: 19596876
[TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model.
Zhanel GG; Voth D; Nichol K; Karlowsky JA; Noreddin AM; Hoban DJ
J Antimicrob Chemother; 2009 Aug; 64(2):364-9. PubMed ID: 19454524
[TBL] [Abstract][Full Text] [Related]
19. Potential utility of a peptide deformylase inhibitor (NVP PDF-713) against oxazolidinone-resistant or streptogramin-resistant Gram-positive organism isolates.
Jones RN; Moet GJ; Sader HS; Fritsche TR
J Antimicrob Chemother; 2004 May; 53(5):804-7. PubMed ID: 15056649
[TBL] [Abstract][Full Text] [Related]
20. [Comparative in vitro activity of daptomycin against gram-positive microorganisms: SENTRY surveillance program, Spain (2002-2006)].
Loza E; Morosini MI; Pascual A; Tubau F; Alcalá J; Liñares J; Hernández-Bello JR; Baquero F; Perea E; Martín R; Jones RN; Cantón R;
Enferm Infecc Microbiol Clin; 2008 Oct; 26(8):489-94. PubMed ID: 19094861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
